Pyridoxal phosphate-responsive epilepsy with resistance to pyridoxine

Area of Science:

• Biochemistry
• Neurology
• Genetics

Background:

• Pyridoxine-dependent epilepsy is a rare genetic disorder characterized by intractable seizures unresponsive to conventional antiepileptic drugs.
• Treatment typically involves high-dose pyridoxine (vitamin B6), which is converted to its active form, pyridoxal phosphate, in the body.
• The precise biochemical mechanisms underlying pyridoxine metabolism and its role in neurotransmitter synthesis are complex.

Observation:

• A female infant presented with severe seizures that were refractory to pyridoxine treatment.
• Remarkably, the infant's seizures showed a significant and rapid response to pyridoxal phosphate administration.
• This differential response indicated a potential issue beyond a simple deficiency of the active cofactor.

Findings:

• The patient's seizures were controlled by pyridoxal phosphate, but not by pyridoxine, suggesting a possible defect in the metabolic pathway converting pyridoxine to pyridoxal phosphate.
• This pathway involves absorption, transportation, phosphorylation, and oxidation, and an abnormality at any step could impair the conversion.
• The underlying cause might involve not only glutamic acid decarboxylase but also defects in the vitamin B6 metabolic cascade.

Implications:

• Pyridoxal phosphate may be a more effective therapeutic agent than pyridoxine for certain patients with suspected pyridoxine-dependent epilepsy.
• Considering pyridoxal phosphate as a first-line treatment could reduce treatment failure rates and delays in seizure control.
• Further research into the specific metabolic defects in pyridoxine-dependent epilepsy is warranted to optimize treatment strategies.